Literature DB >> 23611882

P38 inhibition in COPD; cautious optimism.

Dave Singh.   

Abstract

Entities:  

Keywords:  COPD Pharmacology

Mesh：

Substances：

Year:  2013        PMID： 23611882     DOI： 10.1136/thoraxjnl-2013-203498

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  6 in total

1.  The COPD Pipeline, XXVI.

Authors:  Nicholas Gross
Journal:  Chronic Obstr Pulm Dis       Date:  2015-01-16

Review 2.  Senescence: Pathogenic Driver in Chronic Obstructive Pulmonary Disease.

Authors:  Melissa Rivas; Gayatri Gupta; Louis Costanzo; Huma Ahmed; Anne E Wyman; Patrick Geraghty
Journal:  Medicina (Kaunas)       Date:  2022-06-17       Impact factor: 2.948

3.  Gene expression changes caused by the p38 MAPK inhibitor dilmapimod in COPD patients: analysis of blood and sputum samples from a randomized, placebo-controlled clinical trial.

Authors:  Joanna C Betts; Ruth J Mayer; Ruth Tal-Singer; Linda Warnock; Chris Clayton; Stewart Bates; Bryan E Hoffman; Christopher Larminie; Dave Singh
Journal:  Pharmacol Res Perspect       Date:  2014-12-09

4.  The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.

Authors:  Marie Fisk; Joseph Cheriyan; Divya Mohan; Julia Forman; Kaisa M Mäki-Petäjä; Carmel M McEniery; Jonathan Fuld; James H F Rudd; Nicholas S Hopkinson; David A Lomas; John R Cockcroft; Ruth Tal-Singer; Michael I Polkey; Ian B Wilkinson
Journal:  PLoS One       Date:  2018-03-22       Impact factor: 3.240

5.  p38 mitogen-activated protein kinase determines the susceptibility to cigarette smoke-induced emphysema in mice.

Authors:  Satoshi Marumo; Yuma Hoshino; Hirofumi Kiyokawa; Naoya Tanabe; Atsuyasu Sato; Emiko Ogawa; Shigeo Muro; Toyohiro Hirai; Michiaki Mishima
Journal:  BMC Pulm Med       Date:  2014-05-07       Impact factor: 3.317

Review 6.  P38α MAPK Signaling-A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease.

Authors:  Ursula A Germann; John J Alam
Journal:  Int J Mol Sci       Date:  2020-07-31       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.